# US 11,896,567 B2 · Combination composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,896,567 B2
- Document ID: US11896567B2
- Status: Granted
- Kind: B2
- Application number: 17/943,708
- Filed: 2022-09-13
- Published: 2023-01-05
- Granted: 2024-02-13
- Earliest claimed: 2010-11-04
- Assignees: AFT Pharmaceuticals Limited
- Applicants: AFT Pharmaceuticals Limited
- Inventors: Hartley C. Atkinson
- Web page: https://patentgrep.com/patent/US11896567B2

## CPC

- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/20: Hypnotics; Sedatives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An intravenous composition for providing relief for pain and/or inflammation, the composition having ibuprofen and paracetamol in combination for delivering to a human at each dose: a) approximately 125 mg to approximately 175 mg ibuprofen in combination with approximately 475 mg to approximately 525 mg paracetamol; or b) approximately 275 mg to approximately 325 mg ibuprofen in combination with approximately 975 mg to approximately 1,025 mg paracetamol.

## Claims

### Claim 1

A method of treating pain by intravenously administering to a human, 100 ml of an aqueous solution comprising:
a) 150 mg ibuprofen in combination with 500 mg paracetamol; or
b) 300 mg ibuprofen in combination with 1000 mg paracetamol.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the aqueous solution is administered on a 6 hourly basis.

### Claim 3 (depends on 1)

The method of claim 1, wherein the aqueous solution comprises 150 mg ibuprofen in combination with 500 mg paracetamol.

### Claim 4 (depends on 1)

The method of claim 1, wherein the aqueous solution comprises 300 mg ibuprofen in combination with 1000 mg paracetamol.

### Claim 5 (depends on 2)

The method of claim 2, wherein the aqueous solution comprises 150 mg ibuprofen in combination with 500 mg paracetamol.

### Claim 6 (depends on 2)

The method of claim 2, wherein the aqueous solution comprises 300 mg ibuprofen in combination with 1000 mg paracetamol.

### Claim 7

A method of treating pain by intravenously administering to a human, an aqueous solution comprising:
a) 150 mg ibuprofen in combination with 500 mg paracetamol; or
b) 300 mg ibuprofen in combination with 1000 mg paracetamol, wherein the administration takes place over 15 minutes.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the aqueous solution is administered on a 6 hourly basis.

### Claim 9 (depends on 7)

The method of claim 7, wherein the aqueous solution comprises 150 mg ibuprofen in combination with 500 mg paracetamol.

### Claim 10 (depends on 7)

The method of claim 7, wherein the aqueous solution comprises 300 mg ibuprofen in combination with 1000 mg paracetamol.

### Claim 11 (depends on 8)

The method of claim 8, wherein the aqueous solution comprises 150 mg ibuprofen in combination with 500 mg paracetamol.

### Claim 12 (depends on 8)

The method of claim 8, wherein the aqueous solution comprises 300 mg ibuprofen in combination with 1000 mg paracetamol.

### Claim 13

A method of treating pain by intravenously administering to a human, 100 ml of an aqueous solution comprising:
a) 150 mg ibuprofen in combination with 500 mg paracetamol; or
b) 300 mg ibuprofen in combination with 1000 mg paracetamol, wherein the administration takes place over 15 minutes.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the aqueous solution is administered on a 6 hourly basis.

### Claim 15 (depends on 13)

The method of claim 13, wherein the aqueous solution comprises 150 mg ibuprofen in combination with 500 mg paracetamol.

### Claim 16 (depends on 13)

The method of claim 13, wherein the aqueous solution comprises 300 mg ibuprofen in combination with 1000 mg paracetamol.

### Claim 17 (depends on 14)

The method of claim 14, wherein the aqueous solution comprises 150 mg ibuprofen in combination with 500 mg paracetamol.

### Claim 18 (depends on 14)

The method of claim 14, wherein the aqueous solution comprises 300 mg ibuprofen in combination with 1000 mg paracetamol.